8:03AM Optimer Pharma announced that Astellas Pharma Europe achieved the first sales of DIFICLIR tablets, triggering a EUR 10 mon milestone payment from Astellas to Optimer (OPTR) 15.39 : Under the 2011 collaboration and license agreement, Optimer granted to Astellas development and commercialization rights in Europe and certain other countries in the Middle East, Africa and the Commonwealth of Independent States. The European Commission granted Marketing Authorization for DIFICLIR tablets for the treatment of adults with Clostridium difficile infections in December, 2011.
Market Data 
Markets 
AI
